FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Oct. 07, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Fair Value Disclosures [Abstract] | |||
| Available for sale securities aggregate cost | $ 1,751,000 | $ 3,551,000 | |
| Investments included net unrealized gains (losses) | (97,000) | 3,300,000 | |
| Gross unrealized losses | 180,000 | 213,000 | |
| Gross unrealized gains | 83,000 | 3,500,000 | |
| Marketable equity securities | $ 1,200,000 | $ 1,000,000.0 | |
| Warrant description | On October 7, 2025, Zimmer Biomet Holdings, Inc. (“Zimmer Biomet”) announced that it had completed its acquisition of Monogram and soon after the announcement we received $4.04 per share in cash for each of the 2,212,378 common shares we owned of Monogram prior to the close of the acquisition, for total proceeds of $8.9 million. Accordingly, in our second quarter of fiscal 2026, we recorded a realized gain in the amount of $6.8 million. In addition, we received 2,212,378 non-tradeable contingent value rights (“CVRs”) payable in cash to us if Monogram completes five milestones related to proof-of concept, FDA 510(k) approval, and specific revenue milestones. The CVR payments, if earned, will range in value from $1.04 to $3.43 per CVR for a total amount of $12.37 per CVR should all milestones be attained. | ||